Bergen, Norway 9 June 2022 

Lifecare has recently concluded successful in-vitro test results of the
miniaturized Sencell sensor. This represents a milestone achievement of the
Sencell development, and the impact of the in-vitro tests reaches even further.
Learn more about the importance of these test results, as well as further
increase of staff in the Lifecare Group, a nationwide press coverage in several
Norwegian regional papers, a continued positive revenue at Lifecare Laboratory,
and download Lifecares updated investor presentation.


Read more in the Lifecare June newsletter:
https://lifecare.no/news/information-from-lifecare-june/


Lifecare's updated investor presentation is attached, it can also be downloaded
at the company's webpage.


This is Lifecare 
Lifecare is a Bergen-based technology company developing a miniaturized
implantable long-term sensor for correct and continuous monitoring of blood
sugar in people with diabetes. The Company's patented technology also has the
potential for use in various biomarkers. Lifecare AS is listed on Euronext
Growth (LIFE). 

Further information Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no,
+47 40 05 90 40 

This stock exchange announcement was published by Kine Hereid, Investor
Relations at Lifecare AS, on 09.06.22 at 08:30 CET.